Single-domain antibodies are emerging as credible alternatives due to their target specificity, high affinity, and cost-effective recombinant production.
Diana M. Leite
Advertisement
Diana M. Leite is a PhD student at the School of Pharmacy and Biomedical Sciences, University of Portsmouth, St Michael’s Building, White Swan Road, Portsmouth PO1 2DT, United Kingdom.
Articles by Diana M. Leite
Advertisement
Latest Updated Articles
Single-Domain Antibodies for Brain TargetingAugust 1st 2014
Advertisement
Advertisement
Trending on BioPharm International
1
Zai Lab’s Long-Acting Atopic Dermatitis Bispecific Points to Every-12-Week Dosin
2
FDA Reportedly Pauses National Priority Voucher Pilot and Pauses CRL Publication
3
ImvivaBio’s Dual-Target Allogeneic CAR-T Sustains Lupus Remission Through 12 Months
4
FDA Grants Kamau RMAT Designation to Nula-cel for Sickle Cell Disease
5